Literature DB >> 11497442

Cloning and characterization of a Moraxella bovis cytotoxin gene.

J A Angelos1, J F Hess, L W George.   

Abstract

OBJECTIVE: To identify the Moraxella bovis cytotoxin gene. PROCEDURE: Hemolytic and nonhemolytic strains of M. bovis were compared by use of western blotting to identify proteins unique to hemolytic strains. Oligonucleotide primers, designed on the basis of amino acid sequences of 2 tryptic peptides derived from 1 such protein and conserved regions of the C and B genes from members of the repeats in the structural toxin (RTX) family of bacterial toxins, were used to amplify cytotoxin-specific genes from M. bovis genomic DNA. Recombinant proteins were expressed, and antisera against these proteins were produced in rabbits.
RESULTS: Several proteins ranging in molecular mass from 55 to 75 kd were unique to the hemolytic strain. An open reading frame encoding a 927-amino acid protein with a predicted molecular mass of 98.8 kd was amplified from M. bovis genomic DNA. The deduced amino acid sequence encoded by this open reading frame was homologous to RTX toxins. Antisera against the recombinant carboxy terminus encoded by this open reading frame neutralized hemolytic and cytolytic activities of native M. bovis cytotoxin. CONCLUSIONS AND CLINICAL RELEVANCE: A gene was identified in M bovis that encodes a protein with sequence homology to other RTX toxins. Results of cytotoxin neutralization assays support the hypothesis that M. bovis cytotoxin is encoded by this gene and belongs in the RTX family of bacterial exoproteins. Identification of this gene and expression of recombinant cytotoxin could facilitate the development of improved vaccines against infectious bovine keratoconjunctivitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11497442     DOI: 10.2460/ajvr.2001.62.1222

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  7 in total

1.  Ocular immune responses in steers following intranasal vaccination with recombinant Moraxella bovis cytotoxin adjuvanted with polyacrylic acid.

Authors:  John A Angelos; Judy M Edman; Munashe Chigerwe
Journal:  Clin Vaccine Immunol       Date:  2013-12-11

2.  Whole genome sequencing of Moraxella bovis strains from North America reveals two genotypes with different genetic determinants.

Authors:  Emily L Wynn; Matthew M Hille; John Dustin Loy; Gennie Schuller; Kristen L Kuhn; Aaron M Dickey; James L Bono; Michael L Clawson
Journal:  BMC Microbiol       Date:  2022-10-21       Impact factor: 4.465

3.  Recombinant Moraxella bovoculi cytotoxin-ISCOM matrix adjuvanted vaccine to prevent naturally occurring infectious bovine keratoconjunctivitis.

Authors:  John A Angelos; V Michael Lane; Louise M Ball; John F Hess
Journal:  Vet Res Commun       Date:  2010-03-10       Impact factor: 2.459

4.  A field trial of autogenous Moraxella bovis bacterin administered through either subcutaneous or subconjunctival injection on the development of keratoconjunctivitis in a beef herd.

Authors:  Harriet J Davidson; Gerald L Stokka
Journal:  Can Vet J       Date:  2003-07       Impact factor: 1.008

5.  Effects of Moraxella (Branhamella) ovis culture filtrates on bovine erythrocytes, peripheral mononuclear cells, and corneal epithelial cells.

Authors:  Henry E Cerny; Douglas G Rogers; Jeffrey T Gray; David R Smith; Susanne Hinkley
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  Relatedness of type IV pilin PilA amongst geographically diverse Moraxella bovoculi isolated from cattle with infectious bovine keratoconjunctivitis.

Authors:  John A Angelos; Kristin A Clothier; Regina L Agulto; Boguslav Mandzyuk; Morten Tryland
Journal:  J Med Microbiol       Date:  2021-02       Impact factor: 2.472

7.  MALDI-TOF MS Biomarker Detection Models to Distinguish RTX Toxin Phenotypes of Moraxella bovoculi Strains Are Enhanced Using Calcium Chloride Supplemented Agar.

Authors:  Matthew M Hille; Michael L Clawson; Aaron M Dickey; Justin H Lowery; John Dustin Loy
Journal:  Front Cell Infect Microbiol       Date:  2021-03-16       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.